Senores Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹138Cr
- +72.5% YoY
- +21.1% QoQ
- Net profit
- ₹21Cr
- +90.9% YoY
- +16.7% QoQ
- Margin
- 25%
- −2 pp YoY
- +8 pp QoQ
Guidance rank: #13 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Senores Pharmaceuticals anticipates 20%-30% CAGR growth in U.S. Senores Pharmaceuticals expects a top-line growth of approximately 50% in FY26 over FY25.
From Senores Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Senores Pharmaceuticals anticipates 20%-30% CAGR growth in U.S. regulated market revenue going forward.
- FY26 revenue guidance is around INR 600-650 crores, a 50% growth year-on-year, with 100% net profit growth.
- CDMO segment expected to contribute about INR 200 crores in FY26 with 20%-30% CAGR growth in subsequent years.
- Emerging markets show strong growth with 32% Y-o-Y revenue increase; EBITDA expected to improve from 6% to mid-teens (~10-15%) by next year.
- Product launches in H2 FY26 will further boost sales, with peak impact expected in FY27.
- Total US manufacturing capacity expansion will support volume growth, including four lines by end of the year.
2 more points from Senores Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Senores Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current capex planned at around INR 100-150 crores for the year (FY26), down from earlier estimates of INR 250 crores.
- Capex split between US and India manufacturing facilities.
- In the US:
- Four oral solid manufacturing lines planned, with the third line operational by Q3 FY26 and the fourth by year-end.
- Expansion of US plant capacity from 1.2 billion to 2 billion units.
- India facility:
- Strategic investment to cater to new markets (e.g., Brazil, Mexico, EU).
- Part of capex funding through internal accruals, part debt, and IPO proceeds.
- Some capex to spill into next year (around INR 50 crores).
2 more points from Senores Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Senores Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Current CDMO-CMO order book stands at approximately USD 23 million as of the beginning of Q1FY26.
- The order book typically spans an execution timeframe of 12 to 18 months, with rolling and long-term contracts.
- The company maintains ongoing discussions with multiple partners, indicating potential for additional orders beyond the current book.
- Expected CDMO revenues for FY26 are around INR 200 crores, with growth visibility and confidence to meet this target.
2 more points from Senores Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Senores Pharmaceuticals Ltd — Quarterly revenue & net profit
Senores Pharmaceuticals Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 138 | 80 | +72.5% | 114 | +21.1% |
| Operating profit (EBITDA) | 34 | 21 | +61.9% | 19 | +78.9% |
| Operating margin | 25% | 27% | -2 pp | 17% | +8 pp |
| Profit before tax | 26 | 13 | +100% | 21 | +23.8% |
| Net profit (PAT) | 21 | 11 | +90.9% | 18 | +16.7% |
| EPS (₹) | 4.28 | 3.23 | +32.5% | 3.87 | +10.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹192 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Senores Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Senores Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Senores Pharmaceuticals Ltd Q1 FY26 results?
Senores Pharmaceuticals anticipates 20%-30% CAGR growth in U.S. Senores Pharmaceuticals expects a top-line growth of approximately 50% in FY26 over FY25.
What is Senores Pharmaceuticals Ltd share price analysis?
Senores Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.9 with a market cap of ₹6,805 Cr. Investors should review the full earnings analysis for detailed insights.
Is Senores Pharmaceuticals Ltd planning capital expenditure?
Current capex planned at around INR 100-150 crores for the year (FY26), down from earlier estimates of INR 250 crores.
Keep Senores Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
